Novel Therapies for the Treatment of HER2-Positive Advanced Breast Cancer: A Canadian Perspective
The advent of anti-HER2 targeted therapies has dramatically improved the outcome of HER2-positive breast cancer; however, resistance to treatment in the metastatic setting remains a challenge, highlighting the need for novel therapies. The arrival of new treatment options and clinical trials examini...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-04-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/29/4/222 |
| _version_ | 1827621160462843904 |
|---|---|
| author | Cristiano Ferrario Anna Christofides Anil Abraham Joy Kara Laing Karen Gelmon Christine Brezden-Masley |
| author_facet | Cristiano Ferrario Anna Christofides Anil Abraham Joy Kara Laing Karen Gelmon Christine Brezden-Masley |
| author_sort | Cristiano Ferrario |
| collection | DOAJ |
| description | The advent of anti-HER2 targeted therapies has dramatically improved the outcome of HER2-positive breast cancer; however, resistance to treatment in the metastatic setting remains a challenge, highlighting the need for novel therapies. The arrival of new treatment options and clinical trials examining the efficacy of novel agents may improve outcomes in the metastatic setting, including in patients with brain metastases. In the first-line setting, we can potentially cure a selected number of patients treated with pertuzumab + trastuzumab + taxane. In the second-line setting, clinical trials show that trastuzumab deruxtecan (T-DXd) is a highly effective option, resulting in a shift from trastuzumab emtansine (T-DM1) as the previous standard of care. Moreover, we now have data for patients with brain metastases to show that tucatinib + trastuzumab + capecitabine can improve survival in this higher-risk group and be an effective regimen for all patients in the third-line setting. Finally, we have a number of effective anti-HER2 therapies that can be used in subsequent lines of therapy to improve patient outcomes. This review paper discusses the current treatment options and presents a practical treatment sequencing algorithm in the context of the Canadian landscape. |
| first_indexed | 2024-03-09T10:58:45Z |
| format | Article |
| id | doaj.art-f5009ed6dae144e081aaa90c68f294df |
| institution | Directory Open Access Journal |
| issn | 1198-0052 1718-7729 |
| language | English |
| last_indexed | 2024-03-09T10:58:45Z |
| publishDate | 2022-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj.art-f5009ed6dae144e081aaa90c68f294df2023-12-01T01:27:37ZengMDPI AGCurrent Oncology1198-00521718-77292022-04-012942720273410.3390/curroncol29040222Novel Therapies for the Treatment of HER2-Positive Advanced Breast Cancer: A Canadian PerspectiveCristiano Ferrario0Anna Christofides1Anil Abraham Joy2Kara Laing3Karen Gelmon4Christine Brezden-Masley5Department of Oncology, McGill University, Montreal, QC H3A OG4, CanadaIMPACT Medicom Inc., Toronto, ON M6S 3K2, CanadaDepartment of Oncology, University of Alberta, Edmonton, AB T6G 2R3, CanadaFaculty of Medicine, Cancer Care Program, Memorial University, St. John’s, NL A1B 3V6, CanadaDepartment of Medical Oncology, University of British Columbia, Vancouver, BC V6T 1Z4, CanadaDepartment of Medicine, University of Toronto, Toronto, ON M5S 1A8, CanadaThe advent of anti-HER2 targeted therapies has dramatically improved the outcome of HER2-positive breast cancer; however, resistance to treatment in the metastatic setting remains a challenge, highlighting the need for novel therapies. The arrival of new treatment options and clinical trials examining the efficacy of novel agents may improve outcomes in the metastatic setting, including in patients with brain metastases. In the first-line setting, we can potentially cure a selected number of patients treated with pertuzumab + trastuzumab + taxane. In the second-line setting, clinical trials show that trastuzumab deruxtecan (T-DXd) is a highly effective option, resulting in a shift from trastuzumab emtansine (T-DM1) as the previous standard of care. Moreover, we now have data for patients with brain metastases to show that tucatinib + trastuzumab + capecitabine can improve survival in this higher-risk group and be an effective regimen for all patients in the third-line setting. Finally, we have a number of effective anti-HER2 therapies that can be used in subsequent lines of therapy to improve patient outcomes. This review paper discusses the current treatment options and presents a practical treatment sequencing algorithm in the context of the Canadian landscape.https://www.mdpi.com/1718-7729/29/4/222breast cancerHER2oncologyhuman epidermal growth factor receptor 2 |
| spellingShingle | Cristiano Ferrario Anna Christofides Anil Abraham Joy Kara Laing Karen Gelmon Christine Brezden-Masley Novel Therapies for the Treatment of HER2-Positive Advanced Breast Cancer: A Canadian Perspective Current Oncology breast cancer HER2 oncology human epidermal growth factor receptor 2 |
| title | Novel Therapies for the Treatment of HER2-Positive Advanced Breast Cancer: A Canadian Perspective |
| title_full | Novel Therapies for the Treatment of HER2-Positive Advanced Breast Cancer: A Canadian Perspective |
| title_fullStr | Novel Therapies for the Treatment of HER2-Positive Advanced Breast Cancer: A Canadian Perspective |
| title_full_unstemmed | Novel Therapies for the Treatment of HER2-Positive Advanced Breast Cancer: A Canadian Perspective |
| title_short | Novel Therapies for the Treatment of HER2-Positive Advanced Breast Cancer: A Canadian Perspective |
| title_sort | novel therapies for the treatment of her2 positive advanced breast cancer a canadian perspective |
| topic | breast cancer HER2 oncology human epidermal growth factor receptor 2 |
| url | https://www.mdpi.com/1718-7729/29/4/222 |
| work_keys_str_mv | AT cristianoferrario noveltherapiesforthetreatmentofher2positiveadvancedbreastcanceracanadianperspective AT annachristofides noveltherapiesforthetreatmentofher2positiveadvancedbreastcanceracanadianperspective AT anilabrahamjoy noveltherapiesforthetreatmentofher2positiveadvancedbreastcanceracanadianperspective AT karalaing noveltherapiesforthetreatmentofher2positiveadvancedbreastcanceracanadianperspective AT karengelmon noveltherapiesforthetreatmentofher2positiveadvancedbreastcanceracanadianperspective AT christinebrezdenmasley noveltherapiesforthetreatmentofher2positiveadvancedbreastcanceracanadianperspective |